EGFR and non-small cell lung carcinoma: Around 10%–30% of non-small cell lung cancer (NSCLC) patients harbored epidermal growth factor receptor (EGFR) mutations, with L858R and exon-19 deletions (19-Del) accounting for 90% of cases.